Long-Term Adherence to Benralizumab and Sustained Clinical Benefits in Patients with Severe Eosinophilic Asthma: Insights from GALERNA, a Retrospective Real-World Study in Spain

Asthma

Real-World Effectiveness Following Benralizumab Use in Patients with Severe Eosinophilic Asthma in Romania: A Retrospective Cohort Study (BREEZE)

J Clin Med

Toma CL, Teodorescu G, Mihălţan FD, Frent S, Ali S, Trenchea M, Constantin AA

doi: 10.3390/jcm15020425

Asthma

Long-Term Clinical and Biological Outcomes of Biologic Therapy in Severe Asthma: 24-Month Real-World Cohort Study from Romania

J Clin Med

Mărginean C, Safta AC, Huțanu D, Budin CE, Ianosi MB, Jimborean G, Ianosi ES

doi: 10.3390/jcm15062444

Asthma

Impact of Health Insurance Type on Access to Biologics and Systemic Corticosteroid Exposure in Patients With Severe Asthma: A Real-World Study From the Korean Severe Asthma Registry (KoSAR)

Allergy Asthma Immunol Res

Sohn KH, Lee SK, Lee HY, Kim SR, Lee SE, Kim JH, Song WJ, Kim SH, Korean Severe Asthma Registry (KoSAR) Investigators

doi: 10.4168/aair.2026.18.2.192

RECOMMENDED

Asthma

Real-World Effectiveness and Safety of Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Multicenter Study

★ 2 Recommended by Dr Marcus Hesse, Faculty Member

Pediatr Pulmonol

Çevik NN, Ocak M, Kocatepe G, Teker NB, Kocacik Uygun DF, Serbes M, Ozcan D, Bingol A, Sekerel BE

doi: 10.1002/ppul.71466

Asthma

Effectiveness of Mepolizumab in Patients with OCS-Dependent Severe Asthma: A Real-World Study

Adv Ther

Bavbek S, Al-Ahmad M, Samaha H, Kathuria PC, Fernandez P, Al Busaidi N, Ibrahim T, Mahboub B, Haider S, Noibi S, Levy G, Al-Lehebi RO

doi: 10.1007/s12325-025-03338-w

Asthma

Asthma exacerbation profile of benralizumab for severe eosinophilic asthma (the BenRex study): a multicentre, prospective cohort study

Lancet Respir Med

Logan J, Martin K, Gillespie L, McConnachie A, Lee WN, Burhan H, Brown T, Faruqi S, Jackson DJ, Kurukulaaratchy R, Mansur AH, Saralaya D, Fowler SJ, Patel P, Brown J, Lordan J, Siddiqui S, Smith SJ, Shah PA, Haldar K, Megremis S, Harrison SA, Brown R, Nelson C, Mistry V, Brown V, Chalmers JD, Djukanovic R, Pavord ID, Heaney LG, Brightling CE, Chaudhuri R

doi: 10.1016/S2213-2600(26)00096-2

Asthma

Tezepelumab in Real-World U.S. Patients with Severe Asthma Across Phenotypes and Underrepresented Populations: The Phase 4 PASSAGE Study

Am J Respir Crit Care Med

Lugogo NL, Akuthota P, Sumino K, Burnette AF, Mathur SK, Lindsley AW, Llanos JP, Marchese C, Ambrose CS, Emmanuel B

doi: 10.1093/ajrccm/aamag225

Asthma

Real-World Response to Dupilumab as Add-on Therapy in Adults and Adolescents with Type 2 Severe Asthma: A Spanish Cohort Study

J Asthma Allergy

Montoro Ferrer A, Moro Moro MDM, Parra Borreguero FM, Moreno-Ancillo A, Extremera Ortega AM, Galindo-Bonilla PA, Jiménez Lara M, Bravo Nieto JM, Jiménez Arroyo M, Lemus Calderón JA, Espinosa de Los Monteros Garde MJ

doi: 10.2147/JAA.S582686

AsthmaRespiratory Tract Infection

Dual Remission in Patients with Moderate-to-Severe Asthma and CRSwNP Treated with Dupilumab: A 24-Month Real-World Study

J Clin Med

Menzella F, Berti A, Cestaro W, Bosi A, Munari S, Gialdini F, Scandiuzzi Piovesan T, Cottini M, Lombardi C, Corsi L, De Corso E

doi: 10.3390/jcm15072787

Related content

Real-World Effectiveness Following Benralizumab Use in Patients with Severe Eosinophilic Asthma in Romania: A Retrospective Cohort Study (BREEZE)

Long-Term Clinical and Biological Outcomes of Biologic Therapy in Severe Asthma: 24-Month Real-World Cohort Study from Romania

Impact of Health Insurance Type on Access to Biologics and Systemic Corticosteroid Exposure in Patients With Severe Asthma: A Real-World Study From the Korean Severe Asthma Registry (KoSAR)

Real-World Effectiveness and Safety of Mepolizumab in Pediatric Severe Eosinophilic Asthma: A Multicenter Study

Effectiveness of Mepolizumab in Patients with OCS-Dependent Severe Asthma: A Real-World Study

Asthma exacerbation profile of benralizumab for severe eosinophilic asthma (the BenRex study): a multicentre, prospective cohort study

Tezepelumab in Real-World U.S. Patients with Severe Asthma Across Phenotypes and Underrepresented Populations: The Phase 4 PASSAGE Study

Real-World Response to Dupilumab as Add-on Therapy in Adults and Adolescents with Type 2 Severe Asthma: A Spanish Cohort Study

Dual Remission in Patients with Moderate-to-Severe Asthma and CRSwNP Treated with Dupilumab: A 24-Month Real-World Study